一种临床阶段的瘤学化合物有选择地向耐药性癌症
bioRxiv : the preprint server for biology
|December 15, 2025
概括
酶激活化合物1 (PAC-1) 是一种铁化剂,而不是酶激活剂,通过破坏铁平衡来杀死癌细胞. 令人惊的是,它通过向铁代谢来有效治疗多药耐药性癌症.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 重新评估现有药物可以揭示新的治疗机制.
- 普罗卡斯活性化化合物1 (PAC-1) 最初被研究为用于癌症治疗的酶激活剂.
研究的目的:
- 为了阐明PAC-1的抗癌机制.
- 研究PAC-1与多药耐药性蛋白1 (MDR1) 的相互作用.
主要方法:
- 使用了基因,生化和生物物理分析.
- 细胞细胞毒性测试是在癌症细胞系上进行的.
- 进行了涉及MDR1的药物流量研究.
主要成果:
- PAC-1表现出细胞毒性,独立于子手的caspases.
- PAC-1 作为一种选择性的铁化剂,破坏细胞铁平衡.
- 表达MDR1的癌细胞表现出对PAC-1的过敏性,这是由于铁耗尽的增加.
结论:
- PAC-1的抗癌活性源于铁化,而不是酶激活.
- 使用PAC-1准铁代谢提供了一种针对耐药癌症的新策略.
- 表达MDR1的癌症代表了可通过铁饥饿疗法利用的脆弱性.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Cancer
53.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.4K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


